{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.2","upperLimit":"5.6","value":"4.4"},{"groupId":"OG001","lowerLimit":"2.9","upperLimit":"4.2","value":"3.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"305"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization to the earlier of the dates of the first documentation of radiographic progressive disease or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive 6.0 mg/kg of DS-1062a.","id":"OG000","title":"DS-1062a 6.0 mg/kg"},{"description":"Participants were randomized to receive 75 mg/m\\^2 docetaxel.","id":"OG001","title":"Docetaxel 75 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set includes all randomized subjects. If a subject was randomized more than once, only one of the participants is included in the Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"From randomization until disease progression or death (whichever occurs first), up to approximately 27 months","title":"Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel","type":"PRIMARY","unitOfMeasure":"months"}